Appointment of Amy Welsh to Chief Commercial Officer prioritizes commercial growth
The company is streamlining the leadership team to align with Twirla’s plan to grow®
James Tursi, MD resigns from the Board of Directors
PRINCETON, NJ, October 7, 2022 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. AGRXa women’s health company, announced today that it has reorganized and streamlined its leadership team to align with its business plan to advance Twirla® (levonorgestrel and ethinylestradiol) growth in the transdermal system. As part of the changes, the Company announced the appointment of Amy Welsh as Chief Commercial Officer, effective November 1, 2022. In addition, James P. Tursi, MD, has informed the Company that effective October 7, he will be stepping down from the Company’s Board of Directors. 2022.
“Our focus in 2022 has been to grow Twirla and develop cash flow positively,” said Al Altomari, chairman and chief executive officer of Agile Therapeutics. “In 2022, we significantly reduced our operating costs by redesigning the way we work to increase efficiency and implementing a plan that we believe will support Twirla’s growth through our Afaxys partnership, the Connected TV campaign (CTV) and the expansion of the telemedicine channel. The changes to Our Leadership Team that we’re announcing today are designed to help us consolidate the efficiencies we’ve achieved across our operations by streamlining my leadership team and continuing to focus on executing our business plan.”
In addition to her current responsibilities as head of Twirla’s marketing team, Ms. Welsh will assume responsibility for all of the company’s commercial functions as Chief Commercial Officer. Ms. Welsh joined the Company in May 2020 as Vice President, Marketing. Prior to joining Agile, Ms. Welsh was Vice President of Marketing at Antares Pharma, Inc. and held various positions of increasing responsibility at AstraZeneca.
The Company has also appointed Geoffrey P. Gilmore to the newly created role of Chief Administrative…
